Aclaris Therapeutics (ACRS) EBITDA (2017 - 2025)
Historic EBITDA for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$14.5 million.
- Aclaris Therapeutics' EBITDA fell 11653.23% to -$14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$141.5 million, marking a year-over-year decrease of 29920.45%. This contributed to the annual value of -$131.9 million for FY2024, which is 5037.29% down from last year.
- Per Aclaris Therapeutics' latest filing, its EBITDA stood at -$14.5 million for Q3 2025, which was down 11653.23% from -$15.4 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' EBITDA ranged from a high of -$468000.0 in Q4 2023 and a low of -$96.9 million during Q4 2024
- Its 5-year average for EBITDA is -$23.3 million, with a median of -$20.1 million in 2022.
- In the last 5 years, Aclaris Therapeutics' EBITDA soared by 9827.1% in 2023 and then plummeted by 2060128.21% in 2024.
- Quarter analysis of 5 years shows Aclaris Therapeutics' EBITDA stood at -$23.0 million in 2021, then decreased by 17.55% to -$27.1 million in 2022, then surged by 98.27% to -$468000.0 in 2023, then crashed by 20601.28% to -$96.9 million in 2024, then skyrocketed by 85.03% to -$14.5 million in 2025.
- Its EBITDA stands at -$14.5 million for Q3 2025, versus -$15.4 million for Q2 2025 and -$14.7 million for Q1 2025.